CISPLATIN PLUS VP-16 COMBINATION CHEMOTHERAPY IN ADVANCED REFRACTORY BREAST-CANCER

ICLI F., GUNEL N., DINCOL D., KARAOGUZ H., DEMİRKAZIK A.

JOURNAL OF SURGICAL ONCOLOGY, cilt.50, sa.4, ss.251-253, 1992 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 50 Sayı: 4
  • Basım Tarihi: 1992
  • Doi Numarası: 10.1002/jso.2930500411
  • Dergi Adı: JOURNAL OF SURGICAL ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.251-253
  • Anahtar Kelimeler: BREAST NEOPLASMS, DRUG THERAPY, CISPLATIN, ETOPOSIDE, PHASE-II, RANDOMIZED TRIAL, ONCOLOGY-GROUP, ETOPOSIDE, CARCINOMA, PLATINUM, DDP
  • Lokman Hekim Üniversitesi Adresli: Hayır

Özet

Twenty-nine patients with advanced refractory breast cancer were treated with cisplatin 20 mg/m2/d and VP-16 100 mg/d for 5 days every 3-4 weeks. Ten patients received mitomycin C 10 mg/m2 every 6 weeks additionally. Partial response was obtained in 10 of 26 evaluable patients (38%). The response rates for the group treated with and without mitomycin C were 40% and 37.5%, respectively. Median response duration was 5.5 months in partial responders. Median survival was 9.5 months for partial responders and 2 months for the rest of the patients. Cisplatin and VP-16 combination can be considered as a salvage treatment in heavily pretreated patients with advanced breast cancer.